Lorix Plus

Quick links to important sections

Lorix Plus

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorix Plus

Property Description
Active ingredient Permethrin and Crotamiton
Form Lotion or Cream (Topical)
Pharmacological class Scabicides, Pediculicides, and Antipruritics
Common use Treatment of parasitic skin infestations and associated itching
Origin Synthetic Compounds

Lorix Plus is a defined topical pharmaceutical preparation containing the two chemically distinct active ingredients, Permethrin and Crotamiton, in a soothing external base like a cream or lotion. This medicine is classified as a potent antiparasitic agent, strategically engineered to deliver comprehensive treatment against parasitic infestations of the skin and hair. It falls into the core pharmacological classes of Scabicides and Pediculicides.

What Type of Drug is Lorix Plus?

Lorix Plus is categorized fundamentally as a dual-action, synthetic pyrethroid-based agent. The medicine is placed in the primary pharmacological classes of Scabicides and Pediculicides due to its confirmed ability to eradicate mites and lice. The formulation is provided as an external preparation—a lotion or cream—applied via the topical route of administration. As a regionally recognized product, the drug utilizes this specific combination to offer enhanced therapeutic benefit over some older single-active agents.

Composition: Permethrin and Crotamiton

The formulation relies on the strategic blend of its two synthetic chemicals. Permethrin functions as the primary ectoparasiticide, working by disrupting the nervous system of the parasites to cause paralysis and death. The second active component, Crotamiton, serves as a dedicated antipruritic agent, though it also exhibits properties against the scabies mite. Research supports the efficacy of Crotamiton in relieving the pruritus associated with various skin conditions, even separate from its antiparasitic action. The inclusion of Crotamiton ensures the treatment directly addresses the patient's discomfort and irritation.

General Therapeutic Purpose and Benefit

The overarching purpose of Lorix Plus is to provide a complete solution for these cutaneous conditions through simultaneous action. The action of Permethrin ensures the necessary scabicidal and pediculicidal activity to eliminate the root cause of the infestation. Concurrently, the antipruritic effect of Crotamiton provides direct, rapid relief from the severe and debilitating pruritus that often accompanies these conditions, optimizing patient comfort from the start of the treatment process.

Regulatory References

  1. NIH StatPearls on Permethrin

What side effects are possible with Lorix Plus?

Possible Side Effects and Safety Information

The safety profile of Lorix Plus (Permethrin and Crotamiton) is primarily characterized by localized skin reactions and specific restrictions for use in vulnerable populations, as documented in regulatory sources.

Adverse Reaction Scope (Regulatory Categories) Details from Official Labeling
Common/Expected Reactions (Skin and Subcutaneous Tissue Disorders) The most frequently reported effects are mild, transient skin symptoms, including burning, stinging, tingling, redness (erythema), mild rash, or eczema. These are often associated with the underlying condition (scabies) and may be more pronounced in severe cases.
Duration-Related Symptom Patterns Itching (pruritus) may persist for up to four weeks following treatment. This is typically attributed to an allergic reaction to dead mites and is not an indication of treatment failure.
Serious Adverse Reactions (Rare) Although uncommon, a severe allergic reaction (hypersensitivity) to the components, such as anaphylaxis or angioedema, is a possibility with topical medications and requires immediate medical attention.
Safety-Related Restrictions & Contraindications The medication is strictly for external use only and is contraindicated in individuals with a known allergy to permethrin, crotamiton, or related substances (pyrethroids/pyrethrins). Avoid contact with the eyes; if contact occurs, the area should be rinsed immediately with water.
Population-Specific Safety Considerations Pregnancy: Use is generally not advised, especially in the first trimester, due to limited safety data. Lactation: It is unknown if the medication is excreted in human milk; use near the nipples should be avoided. Pediatrics: Safety and effectiveness have not been established for infants less than two months of age.

These safety classifications emphasize that the risks associated with this medication are predominantly local and related to skin irritation, while clearly defining the patient groups and physical constraints under which the product should not be used or used only with caution.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Lorix Plus

Overdose Scope

Property Regulatory Statement
Documented Overdose Presentations: The primary risk for systemic overdose is accidental oral ingestion of the topical formulation, which may lead to manifestations such as nausea, vomiting, dizziness, abdominal pain, and headache [NIH].
Physiological Systems Affected: Gastrointestinal system (vomiting, irritation) and Central Nervous System (dizziness, headache). Severe overexposure can rarely affect the CNS profoundly [FDA Prescribing Information].
Exposure-Related Factors: Overdose is primarily associated with oral ingestion; excessive application or absorption through broken skin is a less common theoretical risk for systemic exposure [MHRA SmPC].
Population-Specific Overdose Notes: Pediatric patients are noted in regulatory information as a population potentially more vulnerable to accidental oral ingestion and subsequent systemic effects [NIH].
Emergency-Response Statements: Seek immediate medical attention following any known or suspected accidental oral ingestion [NIH]. Contact a Poison Control Center at once for advice [NIH].
When Immediate Medical Help is Required: Immediate medical help is mandated for any suspected or known ingestion. Emergency care is required if serious systemic symptoms, such as seizures or loss of consciousness, are present [FDA Prescribing Information].

Overdose Classifications (High-Level)

Classification Regulatory Statement
Severity Classification: Accidental overdose has the potential for severe or life-threatening effects, particularly neurological complications like seizures, following massive ingestion [FDA Prescribing Information].
Overdose-Context Constraints: No specific antidote is known for this combination, as documented in official labeling, directing management toward symptomatic and supportive treatment [MHRA SmPC].

Connection to the Overall Overdose Profile

Regulatory documents define the Lorix Plus overdose profile predominantly by the risk of systemic toxicity resulting from accidental oral ingestion, detailing a range of gastrointestinal and neurological symptoms. The official structure mandates immediate help-seeking upon any ingestion due to the possibility of severe complications like seizures. Documentation confirms that management is limited to label-documented symptomatic and supportive care.

Therapeutic Uses of Lorix Plus

What Lorix Plus Treats: Main Uses and Benefits

Lorix Plus is a combination medication that supports the management of symptoms linked to systemic imbalance and heightened physiological activity, primarily those associated with allergic rhinitis. The dual-ingredient formulation offers supportive management for patients experiencing both nasal and non-nasal discomfort.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, such as sneezing, runny nose, itchy/watery eyes, and nasal congestion, symptoms related to inflammatory or irritative states. The montelukast component is applied in addressing symptoms linked to organ-specific functional stress and is relevant for easing discomfort associated with allergic rhinitis. This combination may assist with symptoms in scenarios where they escalate temporarily, providing supportive relief when symptoms interfere with routine activities.

The medication is commonly used to help manage the symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. It assists with supporting functional stability and is relevant in managing conditions characterized by periods of heightened symptoms, especially those involving inflammatory or irritative processes.

“This combination contributes to easing the overall symptom load during periods of heightened discomfort.”


Quick Fact: Supports management of symptoms related to inflammatory or irritative states.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lorix Plus?

Official regulatory labeling for Lorix Plus defines specific populations eligible for treatment and those who are strictly excluded. The medicine is contraindicated for any individual with a known hypersensitivity or allergy to its active ingredients, Permethrin or Crotamiton, or to related substances like pyrethrins and chrysanthemums.

Eligibility and Age Restrictions

  • Contraindicated: The medicine is contraindicated for use in infants under 2 months of age, as safety and efficacy have not been established.
  • Conditional Use: While approved for children 2 months and older, those up to 3 years of age should only be treated under close medical supervision.
  • Limited Data: Clinical data for older adults (65 years and over) is limited, and increased skin sensitivity cannot be ruled out.

Restricted Use in Special Populations

  • Pregnancy and Lactation: Use during pregnancy or lactation is not recommended by regulatory authorities unless a healthcare provider determines the treatment is clearly necessary. During breastfeeding, application to the nipple area must be strictly avoided.
  • Skin Integrity: The preparation must not be applied to acute exudative dermatoses, open wounds, broken, raw, or severely inflamed skin. Application must also be strictly avoided in the eyes and on mucous membranes.

These constraints establish the official regulatory boundaries for use based on factors like age, allergies, and the integrity of the application site.

What should I know about interactions with other medicines?

The interaction profile for Lorix Plus (Permethrin and Crotamiton) is defined by its topical route of administration, which leads to minimal systemic absorption of its active ingredients. Consequently, regulatory documentation has established no systemic drug–drug, metabolic enzyme (CYP-mediated), or transporter-based interactions. Likewise, no formal interactions with food, alcohol, or herbal products are documented in official prescribing information.

The primary interaction requirements are local and involve administration timing and pharmacodynamic effects at the application site. Official regulatory restrictions mandate that all other topical medicines, cosmetics, and steroids must be discontinued prior to treatment with Lorix Plus. This administration timing rule is essential to prevent interference with the efficacy of the active ingredients.

A specific pharmacodynamic caution exists concerning the co-administration of topical corticosteroids. These preparations must be withheld before using Lorix Plus to treat any concurrent eczematous-like reactions. This restriction is based on the documented risk that using corticosteroids could locally suppress the skin’s response, potentially exacerbating the underlying parasitic infestation. This mandated separation rule and the caution regarding topical steroids represent the full scope of officially documented interaction patterns for this medicine.

Mechanism of Action

The action of this preparation is based on a dual-mechanistic strategy that influences two separate biological systems: the neurological function of the parasite and the sensory signal transmission of the human host.

Disruption of Parasite Neural Function

This domain centers on the neurotoxic mechanism of Permethrin, which acts on the ectoparasite's voltage-gated sodium channels ( VGSCs) in the neuronal membranes. Permethrin's binding causes the prolonged opening of these channels, leading to sustained sodium ion influx and neuronal membrane hyperexcitability. This cascade results in the complete loss of coordinated motor and respiratory control, culminating in the cessation of life functions.

Peripheral Modulation of Sensory Signal Transmission

This domain involves Crotamiton, which acts to modulate activity in the peripheral sensory pathways of the host's skin. Crotamiton exerts its effect by inhibiting the Transient Receptor Potential Vanilloid 4 ( TRPV4) ion channel and suppressing H1-receptor-mediated signals in cutaneous sensory nerves. This mechanistic adjustment lowers the excitability of these nerves, thereby limiting the downstream transmission of neurogenic signals to the central nervous system.

Dosage and Administration Information

How to Use Lorix Plus: Official Administration Guidelines

Lorix Plus is designated exclusively for Topical (Cutaneous) administration, meaning it is applied directly to the surface of the skin. The official usage guidelines establish a specific, time-bound regimen rather than daily dosing.

The standard adult course involves a single application of the cream, typically using up to 30 grams, which is massaged thoroughly into the skin to ensure full-body coverage from the neck to the soles of the feet.


Application Protocol

  • Contact Time: The treatment is characterized by a required contact period where the preparation must remain on the skin for 8 to 14 hours to complete the course of therapy.
  • Removal: After this duration has passed, the product must be completely removed from the body by taking a shower or bath.
  • Retreatment: The treatment is generally designed as a single application. A second application is only officially considered advisable if evidence of live parasites persists after a 7 to 14 day interval.

Administration Specifics and Adjustments

Age-Group Administration Rules:

Age Group Key Procedural Requirement
Infants and Older Adults Application must be extended to include the scalp, face, ears, and neck.
Children under 2 years Use of the medicine is recommended only under medical supervision.

Special Procedural Conditions:

  • The cream should be applied to skin that is clean, dry, and cool, and not immediately after a hot bath.
  • If hands are washed during the 8–14 hour treatment period, the preparation must be reapplied to the hands.

Recent Clinical Evidence

Research evidence / Overview of studies for Lorix Plus


Research on Mite Infestation (Scabies) and Itching Relief

Research on Lorix Plus, a medicine containing two active components, has explored contexts involving mite infestation (scabies) and the associated itching (pruritus). The evidence base is largely built upon Randomized Controlled Trials (RCTs) and systematic reviews that research examined how the medicine's individual components performed against other treatments and non-active controls. Studies explored patient populations diagnosed with scabies, including adults, as well as some groups of children and infants (as young as two months old).

In these studies, researchers monitored two main things: whether the clearance of parasites was studied for and whether there were changes in patient-reported outcomes describing perceived discomfort, specifically the severity of the itching. Findings describe patterns observed in the studies regarding mite clearance rates, and some trials reported how symptoms evolved for patients experiencing pruritus. Evidence contributes to understanding symptom patterns over the short-term treatment period, which is typically one month.

Duration of Study Follow-up and Long-Term Data

The clinical evidence for Lorix Plus is derived from studies that had follow-up durations that were limited, primarily focusing on the short-term symptom patterns and outcomes. For mite infestation, the crucial time for assessment typically occurred at two or four weeks after treatment to confirm immediate status or failure.

Research so far provides insight into short-term changes only and does not fully characterize the long-term effects of treatment. Therefore, there is limited information for long-term outcomes such as sustained cure or recurrence over several months. These extended outcomes are not fully established, and long-term effects are not fully established.

Research Gaps and Uncertainties

Several areas exist where the research is still ongoing or evidence is limited, reflecting the current landscape of scientific investigation for Lorix Plus.

One key area of uncertainty is the specific therapeutic function of the combination itself. While studies explored the individual components extensively, comparative evidence is lacking from dedicated trials that specifically evaluated whether the combination of Permethrin and Crotamiton was associated with greater parasitic clearance than the Permethrin component alone. Furthermore, issues surrounding resistance of mites and lice to the Permethrin component was observed in some studies globally. This means that the research exploring short-term symptom changes may vary significantly based on the local presence of resistant parasites.

Key Studies & References Label: PERMETHRIN cream 5% w/w cream - DailyMed (NIH)

Frequently Asked Questions (FAQ)

Common questions about Lorix Plus (FAQ)


Q: Is Lorix Plus used for long-term conditions or just temporary problems?

Official regulatory documents indicate that Lorix Plus is a treatment designed for acute or temporary infestations. The standard course involves a single application with a required contact time of 8 to 14 hours. A second application is only described as advisable if evidence of the infestation remains after a 7 to 14 day period, which aligns with management for specific, time-limited problems.


Q: Does Lorix Plus cause weight gain or weight loss for most users?

Official product information does not list systemic effects such as weight gain or weight loss among the commonly expected side effects. The known adverse reactions are primarily related to localized, transient skin symptoms, such as burning or stinging at the application site.


Q: I forgot a dose of Lorix Plus. What is the rule for the next step?

The proper use of this topical preparation requires it to remain on the body for a continuous period of 8 to 14 hours to ensure effectiveness. If a specific area, such as the hands, is washed during this time, the preparation is officially described as needing to be reapplied to that area to maintain the required coverage.


Q: How long does the effect of one dose of Lorix Plus typically last?

The medicine is designed to complete its primary action of eliminating the parasite during the 8-to-14 hour contact period. Clinical research generally assesses the success of the treatment at follow-up visits scheduled two or four weeks after the single application.


Q: Does taking Lorix Plus affect my ability to drive or operate machinery?

Official information for one of the active components mentions that side effects like dizziness have been noted in some patient reports. Because of the potential for dizziness, individuals may need to consider how they react to the medicine before engaging in tasks that require full attention.


Q: What happens if I stop taking Lorix Plus suddenly?

As Lorix Plus is designed as a single-application topical treatment, official documents do not describe 'withdrawal' symptoms. However, it is described that itching (pruritus) may persist for up to four weeks after treatment, which is typically considered a reaction to the dead mites and not an indication of treatment failure.


Q: Is a headache a common side effect reported in the Lorix Plus studies?

While the most frequently reported side effects are localized skin reactions such as burning and redness, reports of headaches have also been noted since the product's marketing. Official documentation places the greatest emphasis on the common skin-related reactions that occur at the application site.


Q: Is it true that Lorix Plus can cause changes in mood?

Systemic effects, including changes in mood or psychiatric symptoms, are not listed among the common or expected side effects in official regulatory documents. The medicine's known safety profile is predominantly associated with localized reactions.


Q: Does Lorix Plus cause sleeplessness or fatigue?

Official documents do not list systemic effects such as sleeplessness (insomnia) or fatigue among the commonly reported side effects. The safety profile is defined by localized skin-related reactions.


Q: How quickly does Lorix Plus usually start working?

The primary active component is described as acting on the parasite's nervous system soon after application. However, the official administration protocol requires the cream to remain in contact with the skin for 8 to 14 hours to complete the full therapeutic effect.


Q: Is it okay to drink coffee or caffeine while taking Lorix Plus?

Because this product is a topical treatment with minimal systemic absorption, official regulatory documents state there are no formal interactions with food, alcohol, or herbal products. Therefore, no specific restrictions are documented regarding the consumption of caffeine or coffee.


Q: What is the official guidance for Lorix Plus use in older adults (over 65)?

Official guidelines indicate that Lorix Plus is approved for use in older adults (65 years and over). However, regulatory information notes that clinical data for this population is limited, and increased skin sensitivity cannot be ruled out.


Q: How long after starting Lorix Plus should I expect to see its full effect?

Clinical trials for this treatment typically assess the successful clearance of the infestation at a follow-up visit scheduled two or four weeks after the single application. It is described that the symptom of itching may persist for up to four weeks, which is usually not an indication of treatment failure.


Q: Why are people often confused about the proper timing for taking Lorix Plus?

The application process differs significantly from a typical daily oral medicine, which can lead to common questions about timing. The official guidance requires the cream to be massaged thoroughly into the skin, remain in contact for a single, mandatory period of 8 to 14 hours, and then be completely removed by washing.


Q: Are there any religious or cultural dietary restrictions that affect taking Lorix Plus?

Since Lorix Plus is an external, topical medicine with minimal systemic absorption, official regulatory documents state there are no specific restrictions documented concerning food or diet. This includes dietary requirements related to religious or cultural practices.


Q: Can Lorix Plus be taken with antacids or heartburn medication?

Official regulatory documents establish no systemic drug–drug interactions with oral medications, such as antacids or heartburn medicine. This is due to the topical route of administration and the minimal amount of the active ingredients absorbed into the body.


Q: Can Lorix Plus be split in half if the tablet is scored?

Lorix Plus is an external preparation provided as a cream or lotion, not an oral tablet. Therefore, questions about splitting a scored tablet do not apply to this form of medicine.


Q: How does the effectiveness of Lorix Plus change over time?

Research evidence is primarily derived from studies with limited follow-up durations, with outcomes generally assessed over the short-term (up to four weeks). As a result, the sustained cure rate or long-term effects over several months are not fully established in the official data.


Q: Can I take Lorix Plus if I have a history of mental health conditions?

The official safety restrictions listed in regulatory documents focus on allergies to the components, age constraints, and the condition of the skin at the application site. A history of mental health conditions is not listed as a contraindication or required precaution for the use of this medicine.


Q: What does the research say about the long-term safety of Lorix Plus?

Research provides insight into changes and outcomes over the short-term period following treatment. Official documents explicitly state that the long-term effects are not fully established, as the clinical evidence does not fully characterize outcomes over several months.


Q: What are the most common reasons a doctor might prescribe Lorix Plus?

The most common therapeutic uses described in official documents are to provide treatment for parasitic skin infestations (such as mite infestations or lice) and to offer relief from the associated severe itching (pruritus).

How should Lorix Plus be stored and disposed of?

Storage and Handling Requirements

The official labeled instructions define the necessary conditions for storing Lorix Plus to maintain its quality and ensure safe handling.

Storage Scope Regulatory Requirement
Temperature Store at a temperature below 25°C and do not freeze.
Environmental Must be protected from light.
Child Safety Must be kept out of the sight and reach of children.
Handling Risk Fabric (like clothing or bedding) that contacts the product can become easily ignited by a naked flame; users must be warned to keep away from fire.

Disposal Instructions

There are no specific regulatory instructions to flush this medication. Unused or expired product should be discarded following the general guidance for non-flush medicines: mix the medication with an undesirable substance (such as dirt or cat litter), seal it in a container, and dispose of it in the household trash. Carers are advised to wear gloves when applying the cream.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorix Plus found in:

A-Z Index: